CRISPR-cas9 Screening Identified Lethal Genes Enriched in Cell Cycle Pathway and of Prognosis Significance in Breast Cancer

被引:11
|
作者
Sun, Xi [1 ]
Wang, Zheng [1 ]
Chen, Xiaosong [1 ]
Shen, Kunwei [1 ]
机构
[1] Shanghai Jiao Tong Univ, Ruijin Hosp, Sch Med, Comprehens Breast Hlth Ctr,Dept Gen Surg, Shanghai, Peoples R China
基金
中国国家自然科学基金;
关键词
CRISPR-cas9; screening; breast cancer; cell cycle; signature; cell viability; DNA-REPLICATION; CHECKPOINTS; CDKS;
D O I
10.3389/fcell.2021.646774
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Background Lethal genes have not been systematically analyzed in breast cancer which may have significant prognostic value. The current study aims to investigate vital genes related to cell viability by analyzing the CRISPR-cas9 screening data, which may provide novel therapeutic target for patients. Methods Genes differentially expressed between tumor and normal tissue from the Cancer Genome Atlas (TCGA) and genes related to cell viability by CRISPR-cas9 screening from Depmap (Cancer Dependency Map) were overlapped. Kyoto Encyclopedia of Genes and Genomes (KEGG) and Gene Ontology (GO) analysis was conducted to identify which pathways of overlapped genes were enriched. GSE21653 set was randomized into training and internal validation dataset at a ratio of 3:1, and external validation was performed in GSE20685 set. The least absolute shrinkage and selection operator (LASSO) regression was used to construct a signature to predict recurrence-free survival (RFS) of breast cancer patients. Univariate and multivariate Cox regression were used to evaluate the prognostic value of this signature. Differentially expressed genes (DEGs) between high-risk and low-risk patients were then analyzed to identify the main pathways regulated by this signature. Weighted correlation network analysis (WGCNA) was conducted to recognize modules correlated with high risk. Enrichment analysis was then used to identify pathways regulated by genes shared in the overlapped genes, DEGs, and WGCNA. Results A total of 86 oncogenes were upregulated in TCGA database and overlapped with lethal genes in Depmap database, which were enriched in cell cycle pathway. A total of 51 genes were included in the gene signature based on LASSO regression, and the median risk score of 2.36 was used as cut-off to separate low-risk patients from high-risk patients. High-risk patients showed worse RFS compared with low-risk patients in internal training, internal validation, and external validation dataset. Time-dependent receiver operating characteristic curves of 3 and 5 years indicated that risk score was superior to tumor stage, age, and PAM50 in both entire and external validation datasets. Cell cycle was the main different pathway between the high-risk and low-risk groups. Meanwhile, cell cycle was also the main pathway enriched in the 25 genes which were shared among 86 genes, DEGs, and WGCNA. Conclusion Cell cycle pathway, identified by CRISPR-cas9 screening, was a key pathway regulating cell viability, which has significant prognostic values and can serve as a new target for breast cancer patient treatment.
引用
收藏
页数:11
相关论文
共 50 条
  • [21] Genome-Wide CRISPR-Cas9 Screening and Identification of Potential Genes Promoting Prostate Cancer Growth and Metastasis
    Wang, Wei
    Yuan, Dongbo
    Jiang, Kehua
    Li, Ruidong
    Qu, Han
    Jiang, Fu-Neng
    Zhong, Wei-De
    Sun, Fa
    Jia, Zhenyu
    Zhu, Jianguo
    CURRENT CANCER DRUG TARGETS, 2023, 23 (01) : 71 - 86
  • [22] Genome-Scale CRISPR-Cas9 Synthetic Lethal Screening of AML Cell Line Identified Functional Modulators of Etoposide Resistance Predictive of Clinical Outcome in AML Patients
    Rafiee, Roya
    Sobh, Amin
    Elsayed, Abdelrahman H.
    Tagmount, Abderrahmane
    Vulpe, Chris D.
    Lamba, Jatinder K.
    BLOOD, 2019, 134
  • [23] Forward genetics using CRISPR-Cas9 in intestinal organoids identified novel colorectal tumor suppressor genes
    Takeda, Haruna
    CANCER SCIENCE, 2018, 109 : 782 - 782
  • [24] Genome-scale CRISPR-Cas9 knockout screening in nasopharyngeal carcinoma for radiosensitive and radioresistant genes
    Zhou, Ziyan
    Chen, Gang
    Shen, Mingjun
    Li, Jixi
    Liu, Kang
    Liu, Ming
    Shi, Shuo
    Chen, Wei
    Chen, Sixia
    Yin, Yuanxiu
    Qin, Yating
    Su, Xuejin
    Chen, Weimin
    Kang, Min
    TRANSLATIONAL ONCOLOGY, 2023, 30
  • [25] Massively Parallel CRISPR-Cas9 Knockout Screening in Sheep Granulosa Cells for FSH Response Genes
    Liu, Zaixia
    Dai, Lingli
    Sun, Tianhao
    Liu, Yongbin
    Bao, Yanchun
    Gu, Mingjuan
    Fu, Shaoyin
    He, Xiaolong
    Shi, Caixia
    Wang, Yu
    Guo, Lili
    Zhou, Le
    Ma, Fengying
    Na, Risu
    Zhang, Wenguang
    ANIMALS, 2024, 14 (06):
  • [26] Defining essential genes for human pluripotent stem cells by CRISPR-Cas9 screening in haploid cells
    Yilmaz, Atilgan
    Peretz, Mordecai
    Aharony, Aviram
    Sagi, Ido
    Benvenisty, Nissim
    NATURE CELL BIOLOGY, 2018, 20 (05) : 610 - +
  • [27] Genome-Scale CRISPR-Cas9 Knockout Screening in Nasopharyngeal Carcinoma for Radiosensitive and Radioresistant Genes
    Ziyan, Z.
    Shen, M.
    Jixi, L.
    Kang, L.
    Shi, S.
    Chen, W.
    Chen, S.
    Yin, Y.
    Qin, Y.
    Kang, M.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2021, 111 (03): : E389 - E389
  • [28] Microfluidic Cell Deformability Assay for Rapid and Efficient Kinase Screening with the CRISPR-Cas9 System
    Han, Xin
    Liu, Zongbin
    Zhao, Li
    Wang, Feng
    Yu, Yang
    Yang, Jianhua
    Chen, Rui
    Qin, Lidong
    ANGEWANDTE CHEMIE-INTERNATIONAL EDITION, 2016, 55 (30) : 8561 - 8565
  • [29] Detection of genes responsible for cetuximab sensitization in colorectal cancer cells using CRISPR-Cas9
    Hu, Ting-ting
    Yang, Jia-wen
    Yan, Ye
    Chen, Ying-ying
    Xue, Hai-bo
    Xiang, You-qun
    Ye, Le-chi
    BIOSCIENCE REPORTS, 2020, 40
  • [30] Investigating the mechanisms underlying resistance to chemoterapy and to CRISPR-Cas9 in cancer cell lines
    Tomasi, Francesca
    Pozzi, Matteo
    Lauria, Mario
    SCIENTIFIC REPORTS, 2024, 14 (01)